Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2023
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EJ05
|
| gptkbp:brand |
Ojjaara
|
| gptkbp:CASNumber |
1056634-68-4
|
| gptkbp:chemicalClass |
pyrimidine derivative
|
| gptkbp:developer |
gptkb:Sierra_Oncology
gptkb:GSK |
| gptkbp:hasMolecularFormula |
C23H26N6O3S
|
| https://www.w3.org/2000/01/rdf-schema#label |
momelotinib
|
| gptkbp:indication |
myelofibrosis with anemia
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
JAK1 inhibitor
JAK2 inhibitor |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea diarrhea fatigue thrombocytopenia |
| gptkbp:target |
gptkb:JAK2
gptkb:JAK1 ACVR1 |
| gptkbp:usedFor |
gptkb:myelofibrosis
|
| gptkbp:bfsParent |
gptkb:JAK2
|
| gptkbp:bfsLayer |
7
|